The law firm of Kirby McInerney LLP isinvestigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK). The investigation concerns whether the Companyand/or members of its senior management may have violated federal securities
laws or engaged in other unlawful business practices.
What Happened?
On July 30, 2025, Anika issued a pressrelease announcing topline results from its clinical trial of Hyalofast, “a resorbable, hyaluronic acid scaffold used in conjunction withautologous bone marrow aspirate concentrate (BMAC) for cartilage repair.” The press release stated that “[w]hileHyalofast demonstrated consistent improvements in treated patients across all
measures of pain and function relative to microfracture, the study did not meet
its pre-specified co-primary endpoints. The study was likely impacted by both a
higher subject dropout rate in the microfracture arm and missed visits during
COVID. This resulted in missing data, which reduced the evaluable sample size
and complicated the statistical analysis.” On thisnews, the price of Anika shares declined by $3.06 per share, or approximately
27.42%, to close at $8.10 per share on July 30, 2025.
What Should I Do?
If you purchased or otherwise acquiredAnika securities, have information, or would like to learn more about this
investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email
at investigations@kmllp.com, or fill out the contact form below, to discuss
your rights or interests with respect to these matters at no cost.
Kirby McInerney LLP is a New York-basedplaintiffs’ law firm concentrating in securities,antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation haveresulted in recoveries totaling billions of dollars. Additional information
about the firm can be found at Kirby McInerney LLP’swebsite.
This press release may be consideredAttorney Advertising in some jurisdictions under the applicable law and ethical
rules.